Summit Therapeutics Inc. Increase Decrease In Contingent Liabilities Recognised In Business Combination
Summit Therapeutics Inc. (SMMT) reported Increase Decrease In Contingent Liabilities Recognised In Business Combination of GBP 0 for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination · last filed 2020-06-02
- Summit Therapeutics Inc. increase decrease in contingent liabilities recognised in business combination for the quarter ending 2020-03-31 was 0.00 GBP, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. increase decrease in contingent liabilities recognised in business combination for the quarter ending 2019-03-31 was 2.00K GBP.
- Summit Therapeutics Inc. increase decrease in contingent liabilities recognised in business combination for the quarter ending 2019-01-31 was 106.00K GBP.
- Summit Therapeutics Inc. increase decrease in contingent liabilities recognised in business combination for the quarter ending 2018-01-31 was 0.00 GBP.
| Period end | Increase Decrease In Contingent Liabilities Recognised In Business Combination 3 month | Increase Decrease In Contingent Liabilities Recognised In Business Combination 9 month | Increase Decrease In Contingent Liabilities Recognised In Business Combination 11 month | Increase Decrease In Contingent Liabilities Recognised In Business Combination 12 month | Increase Decrease In Contingent Liabilities Recognised In Business Combination 12 month as first filed |
|---|---|---|---|---|---|
| 2020-03-31 | 0.00 GBP 6-K · filed 2020-06-02 | ||||
| 2019-12-31 | -2.00K GBP 20-F · filed 2020-04-30 | ||||
| 2019-10-31 | 0.00 GBP 6-K · filed 2019-12-17 | ||||
| 2019-03-31 | 2.00K GBP 6-K · filed 2020-06-02 | ||||
| 2019-01-31 | 106.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -754.00K GBP 20-F · filed 2020-04-30 | 754.00K GBP 20-F · filed 2019-03-29 | ||
| 2018-10-31 | -860.00K GBP 6-K · filed 2019-12-17 | ||||
| 2018-01-31 | 0.00 GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 0.00 GBP 20-F · filed 2020-04-30 | |||
| 2017-10-31 | 0.00 GBP 6-K · filed 2018-12-11 | ||||
| 2017-01-31 | 0.00 GBP 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |